Dalrada Financial Announces Acquisitions In Healthcare And Engineering

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

December 28, 2020

Dalrada Financial Corp. announced the Company’s latest acquisition and letters of intent to acquire existing businesses that accelerate its 2021 global market expansion efforts in healthcare and engineering sectors.

Dalrada’s subsidiary, Dalrada Health Products, has executed Letters of Intent to acquire 100% of U.S.-based Pacific Stem Cells, LLC and International Health Group, Inc. through an all stock and cash exchange agreement. Dalrada’s subsidiary, Dalrada Precision, has also acquired a percentage of shares and ownership of CHP Industrial Solutions located in Malaysia.

Dalrada Financial notes the acquisition of Pacific Stem Cells, LLC would further expand Dalrada Health’s product and services offerings in the healthcare industry. By adding a product line in stem cell treatment that is led by an experienced professional team, Dalrada Health will provide alternative therapies to surgery with a drug-free option. Located in Newport Beach, California, Pacific Stem Cells, LLC holds a solid reputation with a loyal customer base. This new product line allows Dalrada Health to offer state-of-the-art alternative therapies while sustaining profit margins.

The global stem cells market size is expected to reach USD 17.9 billion by 2027, expanding at a CAGR of 8.2%.

Dalrada Health’s addition of International Health Group, Inc. (“IHG”) would add a healthcare training, certification, and staffing service to Dalrada’s portfolio for immediately addressing career placement needs in a burgeoning industry. Since 2006, IHG has created the next generation of nurses and medical assistants with more than 6,000 students graduating from the program. IHG is well-established and continues to certify talented individuals who provide quality compassionate care to thousands of patients.

An industry report highlights The American Nurses Association declares nursing careers are, “…in high demand, with more jobs available through 2022 than any other profession in the U.S.” The report continues to explain, “…nursing is one of the fastest-growing occupations in the U.S.”, according to BLS Employment Projections for 2018-2028. The U.S. healthcare staffing market size for the period of 2020 – 2027 was valued at USD 17.0 billion in 2019 and is estimated to expand at a CAGR of around 5% over the forecast period.

Brian Bonar, Dalrada Financial Chief Executive Officer states, “The acquisitions of Pacific Stem Cells, LLC and International Health Group, Inc. would speed Dalrada’s expansion efforts in the healthcare market while solidifying a channel for existing product and service adoption.”

In addition, Dalrada Financial also acquired a percentage of shares and ownership of Malaysian ISO 9001:2015 & AS9100:2016 certified company CHP Industrial Solutions. This acquisition bolsters Dalrada Precision’s computer numerical control (CNC) and custom part manufacturing capabilities with added machinery, quality assurance processes and teams, and additional factory locations in Malaysia. CHP Industrial Solutions’ customer base includes Fortune 100 clients in semiconductor and data storage, automotive, and aviation. The acquisition of CHP Industrial Solutions allows Dalrada Precision to continue its expansion efforts into vertical markets including major airlines, biotechnology, pharmaceutical, and technology sectors.

The global precision parts market size is projected to reach USD 300 billion by 2025, anticipating a growth rate of 10% during 2020-2025.

Bonar concludes, “As Dalrada addresses market needs for bespoke parts and green energy solutions, the acquisition of CHP International Solutions further expands the Company’s capability of providing our clients cost-effective Engineering and custom precision parts solutions from a strategic geographic location.”



Related Articles